Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

Namita Thapar highlights GLP-1 medications or similar weight loss treatments have gained popularity, but their unauthorised ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide - also known as Ozempic - in suppressing appetite and reducing body weight.

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without ...